Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tempest Therapeutics Inc.

6.78
-0.3300-4.64%
Volume:31.99K
Turnover:221.89K
Market Cap:23.72M
PE:-0.35
High:7.20
Open:7.06
Low:6.61
Close:7.11
Loading ...

Tempest Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
28 Mar

Tempest Therapeutics Inc : Scotiabank Cuts Target Price to $7 From $13

THOMSON REUTERS
·
28 Mar

William Blair Reaffirms Their Buy Rating on Tempest Therapeutics (TPST)

TIPRANKS
·
28 Mar

Press Release: Tempest Reports Year End 2024 Financial Results and Provides Business Update

Dow Jones
·
28 Mar

Jakarta to Deploy Nearly 3,000 Sanitation Officers to Anticipate Eid Holiday

Tempo
·
27 Mar

Tempest Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview

Reuters
·
14 Mar

Tempest Therapeutics Says Familial Adenomatous Polyposis Trial Gets US FDA 'Study May Proceed' Notice

MT Newswires Live
·
13 Mar

BRIEF-Tempest gets FDA nod to begin mid-stage study of its therapy for colon cancer-causing genertic condition

Reuters
·
13 Mar

Tempest Therapeutics Inc - Phase 2 Study to Assess Efficacy of Tpst-1495 in Fap Patients

THOMSON REUTERS
·
13 Mar

FDA Study May Proceed Notice Received for Phase 2 Trial of Tpst-1495 for the Treatment of Familial Adenomatous Polyposis (Fap)

THOMSON REUTERS
·
13 Mar

FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)

GlobeNewswire
·
13 Mar

Tempest Therapeutics Says Amezalpat Receives US FDA Fast Track Status As Treatment for Liver Cancer

MT Newswires Live
·
10 Feb

Tempest Therapeutics granted FTD from FDA for amezalpat

TIPRANKS
·
10 Feb

BRIEF-Tempest Granted Fast Track Designation From The U.S. Food And Drug Administration For Amezalpat

Reuters
·
10 Feb

Tempest Granted Fast Track Designation From the U.S. Food and Drug Administration for Amezalpat to Treat Patients With Hepatocellular Carcinoma

THOMSON REUTERS
·
10 Feb

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
08 Feb

BRIEF-Tempest Receives Orphan Drug Designation From U.S. FDA For Amezalpat

Reuters
·
06 Jan

Tempest Receives Orphan Drug Designation From the U.S. Food and Drug Administration for Amezalpat to Treat Patients With Hepatocellular Carcinoma (Hcc)

THOMSON REUTERS
·
06 Jan

Tempest Therapeutics’ PPARalpha inhibitor receives FDA orphan designation

TIPRANKS
·
17 Dec 2024

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
07 Dec 2024